Search clinical trials for: INSULIN GLARGINE (HOE901)

Total 2830 results

Sanofi

Completed

LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous

Diabetes Mellitus

Czech Republic
RISE Study Group
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

RISE Pediatric Medication Study (RISE Peds)

Type 2 Diabetes | Prediabetes

United States
Emory University
Sanofi

Completed

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy

Diabetes Mellitus

United States
Sanofi

Completed

Self Titration With Apidra to Reach Target Study (START)

Diabetes Mellitus, Type 2

Canada
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Russian Federation, Slovakia, Spain, Ireland, Germany, Turkey, Bulgaria, Hong Kong, Romania, South Africa
Novo Nordisk A/S

Completed

Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

Within-subject Variability of Insulin Detemir in Healthy Volunteers

Healthy | Diabetes

Germany
Sanofi

Completed

A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus (AT-LANTUS)

Diabetes Mellitus, Type 2
Sanofi

Completed

SAM - Skip a Meal - Insulin Glargine, Diabetes Mellitus Type 1

Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice

Diabetes Mellitus

Belgium
Sanofi

Completed

32 Week, Open, Randomized, 2 Way Cross Over Multicentre Trial to Compare Safety & Efficacy of Combination of HOE901 Insulin Analogue Once Daily at Bedtime + Lispro Insulin Before Meals vs NPH Insulin (Twice a Day) + Regular in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1
Novo Nordisk A/S

Completed

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

United States, United Kingdom, France, Netherlands, Finland, Germany, Sweden
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1

United States, Brazil
Sanofi

Completed

Lantus in Prediabetes

Hyperglycemia | Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Denmark
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Sanofi

Withdrawn

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Hyperglycemia | Leukemia

United States
Sanofi

Completed

Lantus Versus Levemir Treat-To-Target (L2T3)

Diabetes Mellitus, Type 2

Korea, Republic of, Russian Federation, Spain, Denmark, Canada, Germany, Ireland, Portugal, Australia, India, Turkey, Netherlands, Sweden, United Kingdom, Finland, Switzerland, Romania, Brazil, Serbia, Taiwan
Newcastle University
Sanofi; Medtronic; Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle Primary Care...

Completed

Prevention of Severe Hypoglycemia in Type 1 Diabetes

Type 1 Diabetes Mellitus

United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Universidad Nacional de Asunción

Completed

Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay

Hyperglycemia | Diabetes

Paraguay
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan, Taiwan
Novo Nordisk A/S

Recruiting

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) (COMBINE 4)

Type 2 Diabetes

United States, China, Italy, Japan, India, Poland, South Africa, Turkey, Greece, Puerto Rico
University of Colorado, Denver
Sanofi

Completed

Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital

Diabetes

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes (SUSTAIN™ 4)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, United Kingdom, France, Argentina, South Africa, Germany, Slovenia, Netherlands, Romania, North Macedonia, Mexico, Puerto Rico
University of Alberta
Sanofi

Completed

Pharmacist Intervention for Glycemic Control in The Community (RxING)

Type 2 Diabetes

Canada
University of Minnesota
Sanofi; Moran, Antoinette, M.D.

Completed

Insulin Glargine Vs Standard Insulin Therapy

Cystic Fibrosis Related Diabetes

United States
Shenzhen Second People's Hospital

Unknown

Study on the Feasibility of Community Doctors Guided by Specialists to Use Basic Insulin

Type 2 Diabetes
Novo Nordisk A/S

Completed

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

Diabetes Mellitus, Type 2

India, United States, Thailand, Japan, Germany, Turkey, Hungary, Malaysia, Poland, South Africa, Czechia, Italy, France, Slovenia
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
Inova Health Care Services

Terminated

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Diabetes Mellitus

United States
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
Novo Nordisk A/S

Completed

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Diabetes Care Center

Unknown

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

Diabetes Mellitus Type 1

United States
Pfizer

Completed

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study for Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Israel
Ruhr University of Bochum

Completed

Chronic Reduction of Fasting Glycaemia With Insulin Glargine Improves First and Second Phase Insulin Secretion in Patients With Type 2 Diabetes

Type 2 Diabetes

Germany
Sanofi

Completed

Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement (SAFIR)

Diabetes Mellitus Type 2
Sanofi

Completed

Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2) (COBIN 2)

Diabetes Mellitus, Type 2

Czech Republic
Novo Nordisk A/S

Completed

Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, Austria, South Africa
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Sweden, Finland, France, Norway
King Faisal Specialist Hospital & Research Center

Completed

Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) (GLUCOSE-in-PN)

Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition

Saudi Arabia
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)

Diabetes Mellitus, Type 2

Croatia, India, Poland, Spain, Serbia, Germany, Slovakia, Slovenia, Turkey, Hungary, Greece, Czechia, Bulgaria, South Africa, Romania, Bosnia and Herzegovina, Estonia, Portugal, Latvia, Lithuania, North Macedonia
Buckinghamshire Healthcare NHS Trust
Novo Nordisk A/S

Unknown

Comparing Long-acting Insulins During Exercise in Type 1 Diabetes

Diabetes Mellitus, Type 1

United Kingdom
Eli Lilly and Company

Completed

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (AWARD-7)

Type 2 Diabetes | Chronic Kidney Disease

Mexico, United States, Hungary, Ukraine, Brazil, Spain, Romania, South Africa, Poland
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin

Diabetes Mellitus, Type 2

United States

3

Subscribe